Semaglutide

CAS 910463-68-2

About the API

Trade name(s) Ozempic
Molecular Formula DB13928
Molecular Weight 4114 g/mol
Physical properties Small Molecule
Therapeutic category Diabetes
Available formulations Injectables

General Information

Cardio-vascular benefits: reduces the risk of the primary composite endpoint of time to first occurrence of either cardiovascular CV death, non-fatal myocardial infarction (heart attack) or nonfatal stroke by 26% vs placebo. Trulicity (Dulaglutide) still has to demonstrate such benefits 2. Superior improvements in glycaemic control vs Sitagliptin (SUSTAIN 2) and Exenatide ER (SUSTAIN 3) 3. HbA1c reduction: a. Comparable HbA1c reduction and weight loss to market-leading GLP-1 agonist Victoza (Liraglutide) b. Proven superiority vs placebo as add-on to basal insulin alone or with metformin 4. Once weekly dosing 5. Marketing experience of Novo Nordisk in the areas of diabetes and Obesity